These results indicate that the loss-of-function mutation of GNA13 is a biomarker for the precision BCL2 inhibitor therapy for GCB-DLBCL and that GNA13 palmitoylation is a potential target for combination therapy with the BCL2 inhibitor to treat GCB-DLBCL with WT GNA13. Here, GNA13 is linked to diffuse large B-cell lymphoma.